Want to see RXRX full AI Analyst Report?
Compare Recursion Pharmaceuticals (RXRX) vs. Competitors
Comparison Results
| Name | Price | Market Cap | P/E Ratio | Yearly Gain | Analyst Consensus | Analyst Price Target | Compare | Top Analysts' Price Target | Smart Score | Follow |
|---|---|---|---|---|---|---|---|---|---|---|
| RXRXRecursion Pharmaceuticals | $4.03 | $2.41B | -3.88 | -28.67% | Moderate Buy | RXRX | ||||
| DNLIDenali Therapeutics | $18.94 | $3.03B | -6.67 | 15.63% | Strong Buy | RXRX vs DNLI | ||||
| NRIXNurix Therapeutics | $26.80 | $2.93B | 10.68 | 109.70% | Strong Buy | RXRX vs NRIX | ||||
| GLUEMonte Rosa Therapeutics | $10.76 | $917.97M | -4.93 | -17.29% | Strong Buy | RXRX vs GLUE | ||||
| ABSIAbSci | $11.13 | $1.91B | -13.91 | 172.13% | Strong Buy | RXRX vs ABSI | ||||
| GENBGenerate Biomedicines, Inc. | $14.46 | $1.86B | -8.56 | 14.31% | Strong Buy | RXRX vs GENB |
Performance Comparison
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| RXRX | Recursion Pharmaceuticals | 4.03 | -1.41 | -25.92% | |
| DNLI | Denali Therapeutics | 18.94 | 3.58 | 23.31% | |
| NRIX | Nurix Therapeutics | 26.80 | 14.18 | 112.36% | |
| GLUE | Monte Rosa Therapeutics | 10.76 | -1.31 | -10.85% | |
| ABSI | AbSci | 11.13 | 7.02 | 170.80% | |
| GENB | Generate Biomedicines, Inc. | 14.46 | 1.81 | 14.31% |
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts